Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422957 | 0.88 | NR3C2 (0.39) | GAAKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL25304437 | 0.86 | CYP2C9 (0.37) | GAAKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL14289250 | 0.86 | CYP2C9 (0.47) | GAAKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL15359768 | 0.85 | GRM6 (0.40) | GAAKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL643173 | 0.85 | AAK1 (0.39) | GAAKMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL20741075 | 0.83 | LMNA (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5774469 | 0.83 | AKR1C3 (0.42) | CYP2C9CYP2C19NPSR1GRM6MTNR1A | |
| SCHEMBL679953 | 0.82 | CA1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20741090 | 0.80 | NR3C2 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2838163 | 0.80 | ELANE (0.46) | GAAKMT2ACES2CES1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | GAA 3927/4885KMT2A 2539/4885GABRA1 665/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | GAA 3775/4885KMT2A 2806/4885GABRA1 558/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | GAA 359/4885KMT2A 2787/4885GABRA1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.